The Penultimate Dance of Belén Garijo, Spain's Most International Woman
Belén Garijo returns to Sanofi as CEO after a successful tenure at Merck, marking a significant transition in her career as she continues to shape the pharmaceutical industry.
After Merck's exit: Belén Garijo takes over at the helm of Sanofi
Belén Garijo, the departing CEO of Merck, is set to lead the French pharmaceutical giant Sanofi following the sudden exit of its former CEO, Paul Hudson.
Paul Hudson Dismissed: The Behind-the-Scenes of a Rapid Dismissal at the Head of Sanofi
Paul Hudson has been replaced as CEO of Sanofi by Belén Garijo amid concerns over the company's research and development progress.
Pharmaceutical Industry: Merck CEO Garijo transfers to Sanofi
The French pharmaceutical company Sanofi unexpectedly replaces its CEO with Belén Garijo, previously at Merck, following Paul Hudson's departure.
Sanofi appoints Spanish Belén Garijo as new CEO to regain operational and stock market momentum
Sanofi has appointed Belén Garijo as its new CEO to address operational challenges and improve stock performance following the dismissal of Paul Hudson.
French giant Sanofi hires the Albacete-born Belén Garijo as CEO 15 years after her departure to the German Merck
Sanofi has appointed Belén Garijo as its new CEO, marking a significant leadership transition for the French pharmaceutical giant.
Sanofi: CEO Paul Hudson Abruptly Dismissed from the French Pharmaceutical Giant
Sanofi has unexpectedly announced the immediate dismissal of its CEO, Paul Hudson, who has held the position for six years, with Belén Garijo set to take over.
Opella changes leadership
Opella, the self-care and vitamins division recently separated from Sanofi, appointed Luis Soares as the new CEO in Mexico, succeeding Matías Caride, and announced a significant investment to enhance its manufacturing hub in Ocoyoacac.
Being well informed about the flu and vaccination: the best health insurance
The article emphasizes the importance of flu vaccination in promoting healthy aging and preventing severe complications and hospitalizations.
The European Union approves a drug that slows the development of type 1 diabetes
The European Commission has approved the marketing of 'Tizeld', the first drug to officially impact the progression of type 1 diabetes in the EU, as announced by the French manufacturer Sanofi.